Sarepta Therapeutics Inc. (NASDAQ: SRPT)’s stock price has gone decline by -10.58 in comparison to its previous close of 146.91, however, the company has experienced a -11.70% decrease in its stock price over the last five trading days. The Wall Street Journal reported on 05/16/23 that Gene-Therapy Investors Have a Powerful Ally: Patients
Is It Worth Investing in Sarepta Therapeutics Inc. (NASDAQ: SRPT) Right Now?
Moreover, the 36-month beta value for SRPT is 0.97.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The average price recommended by analysts for Sarepta Therapeutics Inc. (SRPT) is $177.24, which is $44.32 above the current market price. The public float for SRPT is 83.68M and currently, short sellers hold a 4.89% of that float. On May 25, 2023, SRPT’s average trading volume was 1.81M shares.
SRPT’s Market Performance
SRPT stock saw an increase of -11.70% in the past week, with a monthly gain of 3.69% and a quarterly increase of 3.85%. The volatility ratio for the week is 3.84%, and the volatility levels for the last 30 days are 4.40% for Sarepta Therapeutics Inc. (SRPT). The simple moving average for the last 20 days is -1.46% for SRPT’s stock, with a simple moving average of 7.65% for the last 200 days.
SRPT Trading at -1.59% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.84% of loss for the given period.
Volatility was left at 4.40%, however, over the last 30 days, the volatility rate increased by 3.84%, as shares surge +6.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.99% lower at present.
During the last 5 trading sessions, SRPT fell by -11.70%, which changed the moving average for the period of 200-days by +23.90% in comparison to the 20-day moving average, which settled at $133.71. In addition, Sarepta Therapeutics Inc. saw 1.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Mayo Stephen, who sale 858 shares at the price of $109.92 back on Nov 17. After this action, Mayo Stephen now owns 6,387 shares of Sarepta Therapeutics Inc., valued at $94,311 using the latest closing price.
Chambers Michael Andrew, the Director of Sarepta Therapeutics Inc., purchase 57,100 shares at $104.43 during a trade that took place back on Sep 14, which means that Chambers Michael Andrew is holding 108,178 shares at $5,963,124 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -56.83 for the present operating margin
- +80.51 for the gross margin
The net margin for Sarepta Therapeutics Inc. stands at -75.40. The total capital return value is set at -25.97, while invested capital returns managed to touch -34.71. Equity return is now at value -197.80, with -36.10 for asset returns.
Based on Sarepta Therapeutics Inc. (SRPT), the company’s capital structure generated 420.15 points at debt to equity in total, while total debt to capital is 80.77. Total debt to assets is 51.70, with long-term debt to equity ratio resting at 416.12. Finally, the long-term debt to capital ratio is 80.00.
When we switch over and look at the enterprise to sales, we see a ratio of 13.64, with the company’s debt to enterprise value settled at 0.15. The receivables turnover for the company is 4.33 and the total asset turnover is 0.30. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.13.
Conclusion
To wrap up, the performance of Sarepta Therapeutics Inc. (SRPT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
